

KEY:	Please note the program times as for Lisbon (Portugal)				
PRE CONFERENCE SYMPOSIUM	SPONSORED SYMPOSIUM	SYMPOSIUM	PLENARY LECTURE	FORUM	OTHER EVENT
Please note that On-Demand Sessions are listed at the end of this program.					
Tuesday, March 5, 2024					
	Auditorium I	Auditorium VI+VII	Auditorium II		
07:00 - 08:30	ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)				
08:00 - 15:30		Common Features of Neurodegenerative Diseases: Exploring the Brain-Eye Connection and Beyond: CREATING MEANING OUT OF CHAOS: LINKING BIG DATA TOOLS TO PATHOPHYSIOLOGY, BIOMARKERS, DIAGNOSES AND CLINICAL STUDIES	PRE CONFERENCE SYMPOSIUM (08:00 - 15:30) "BY INVITATION ONLY"		
15:45 - 16:30	OPENING CEREMONY AND AWARDS				
16:30 - 16:35	BREAK				
16:35 - 18:05	PLENARY LECTURE 1: THE GENETICS OF NEURODEGENERATIVE DISEASES – FROM RARE POPULATIONS TO COMMON VARIANTS 2 : ESCAPING DEMENTIA UNTIL EXTREME AGES: WHAT CAN COGNITIVELY HEALTHY CENTENARIANS TEACH US? 3: MS TECHNOLOGIES FOR PLASMA BIOMARKER DEVELOPMENT				
18:05 - 18:15				SHORT BREAK	
18:15 - 19:20	FIRESIDE CHAT				
19:30				WELCOME RECEPTION IN EXHIBITION	

Wednesday, March 6, 2024

Wednesday, March 6, 2024						
	On-Demand Oral					
07:00 - 08:30	ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)					
	Auditorium I	Auditorium VI-VII	Auditorium V	Auditorium VIII	Auditorium II	Auditorium III + IV
08:00 - 08:30	PLENARY LECTURE 4: DONALD L. PRICE MEMORIAL LECTURE CRYO-EM STRUCTURES OF DISEASE FILAMENTS FROM HUMAN BRAINS					
08:30 - 08:40	BREAK					
08:40 - 10:40	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	CEREBROVASCULAR CHANGES, CAA, ARIA	ANCESTRY AND GENETICS OF NEURODEGENERATION	ABETA AGGREGATION AND TOXICITY, PROTEIN MISFOLDING & SYNAPSES	IMMUNITY AND INFLAMMATION IN NEURODEGENERATION	CELL REPLACEMENT THERAPY & DIAGNOSTICS: CELLS, GLIA AND GRAFTS
10:40-11:10	EXHIBITION, PRODUCT THEATER, POSTERS AND COFFEE BREAK					
11:10 - 12:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
12:50 - 14:30	EXHIBITION, PRODUCT THEATER, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
14:30-16:30	FORUM 1: BLOOD-BASED BIOMARKERS (BBM) - HOW DO THEY RELATE TO CSF, DIGITAL TOOLS, AND IMAGING BIOMARKERS? (14:30 - 15:30) FORUM 2: FORUM 2 IMMUNOTHERAPIES IN AD - WHAT ARE THE PRESENT CHALLENGES AND FUTURE BENEFITS? (15:35 - 16:35)	MICROGLIA. TREM1, TREM2, MICROGLIA, NEUROINFLAMMATION	TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 1	ALPHA-SYNUCLEIN, AGGREGATION, MISFOLDING AND SEEDING	GENETICS OF NEURODEGENERATION	APOE: CELL, MOLECULAR AND SYSTEMS BIOLOGY
16:30 - 17:00	EXHIBITION, POSTERS AND COFFEE BREAK					
17:00 - 19:00	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	FLUID BIOMARKERS. AND IMAGING AND DIGITAL TOOLS	TAU MECHANISMS 1	PD AND PSP: ADVANCES IN DIAGNOSIS AND DRUG DEVELOPMENT	ASTROCYTES	TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 2

Thursday, March 7, 2024

Thursday, March 7, 2024						
	On-Demand Oral					
07:00 - 08:30	ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)					
	Auditorium I	Auditorium VI+VII	Auditorium V	Auditorium VIII	Auditorium II	Auditorium III + IV
08:00 - 08:30	PLENARY LECTURE 5: TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER'S DISEASE					
08:30 - 08:40	BREAK					
08:40 - 10:40	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	RESILIENCE AND DRIVERS OF DISEASE PROGRESSION	ALPHA-SYNUCLEIN PATHOGENESIS & TREATMENT STRATEGIES	LIPID DYSREGULATION IN AD AND LBD	GENETICS, EPIDEMIOLOGY	TAU MECHANISMS 2
10:40 - 11:10	EXHIBITION, POSTERS AND COFFEE BREAK					
11:10-12:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
12:50 - 13:50	EXHIBITION, PRODUCT THEATER, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
13:50-15:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	ABETA TARGETING THERAPIES IN AD 1	PREDICTION AND PREVENTION OF COGNITIVE DECLINE	FTD, ALS: TDP-43 , C9ORF72 AND TMEM106B 1	FLUID BIOMARKERS	TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 3
15:50-16:20	EXHIBITION, POSTERS AND COFFEE BREAK					
16:20 - 18:30	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (16:20 - 17:20)	DEMENTIA PREVENTION AND TREATMENT STRATEGIES; DIAGNOSIS AND STAGING OF AD (16:20-18:20)	APOE MECHANISMS AND TREATMENT STRATEGIES (16:20-18:20)	TAU PROPOGATION AND PATHOLOGY (16:20-18:20)	DISEASE MECHANISMS, PATHOPHYSIOLOGY: NEURAL NETWORKS, PLASTICITY (16:20-18:20)	DISEASE MECHANISMS, TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 4 (16:20-18:20)
	FORUM 3: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRRK2, AND GBA PATHOLOGIES (17:30- 18:30)					
18:30 - 18:40	Short Break					
18:40 - 20:20	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					

Friday, March 8, 2024						
	On-Demand Oral					
07:00 - 08:30	ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)					
	Auditorium I	Auditorium VI+VII	Auditorium V	Auditorium VIII	Auditorium II	Auditorium III + IV
08:00 - 08:30	PLENARY LECTURE 6: A BIOLOGIC DEFINITION AND STAGING PLATFORM FOR NEURONAL SYNUCLEIN DISEASE					
08:30 - 08:40	BREAK					
08:40 - 10:40	CHOLINERGIC MECHANISMS IN AD AND PD (1)	HETEROGENEITY AND SIMILARITIES PATHOLOGY OF NEURODEGENERATIVE DISEASES	BRAIN GUT INTERACTIONS MICROBIOME	FLUID BIOMARKERS AND IMAGING 1	THERAPEUTIC TARGETS IN AD: TAU PROTEINS	
10:40 - 11:10	EXHIBITION, POSTERS AND COFFEE BREAK					
11:10 - 12:50	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
12:50 - 13:50	EXHIBITION, PRODUCT THEATER, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
13:50 - 15:50	FLUID BIOMARKERS AND IMAGING 2	FTD, ALS: TDP-43 , C9ORF72 AND TMEM106B 2	THERAPEUTIC INTERVENTIONS IN AD AND PD	PET	SEX SIMILARITIES AND DIFFERENCES IN BIOMARKERS & PATHOPHYSIOLOGY	AD, PD, PSP, MSA, LBD ADVANCES IN DIAGNOSIS AND DRUG DEVELOPMENT
15:50 - 16:20	EXHIBITION, POSTERS AND COFFEE BREAK					
16:20 - 18:30	FORUM 4: TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION - WHAT COULD BE PROMISING STRATEGIES? (16:20 - 17:20)	LEWY BODY ASSOCIATED PATHOLOGIES (16:20-18:20)	MRI (16:20-18:20)	FLUID BIOMARKERS AND IMAGING 3 (16:20-18:20)	MICROGLIA, ASTROGLIA (16:20-18:20)	LRKK2, ALPHA-SYNUCLEIN, DIAGNOSIS AND THERAPEUTIC TARGETS (16:20-18:20)
	FORUM 5: ANTI-TAU THERAPIES IN CLINICAL TRIALS - WHAT ARE THE CHALLENGES AND OPPORTUNITIES FOR A RATIONAL THERAPY? (17:30 - 18:30)					
18:30 - 18:40	Short Break					
18:40-19:40	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	FLUID BIOMARKERS AND IMAGING	PATHOPHYSIOLOGY & THERAPEUTIC TARGETS IN AD	ADVANCES IN AD DRUG DEVELOPMENT 1	α -SYNUCLEINOPATHIES: MECHANISMS, PATHOPHYSIOLOGY AND MODELLING OF PROGRESSION 1	GENETICS, EPIDEMIOLOGY, TRANSCRIPTOMICS IN AD & PD

Saturday, March 9, 2024

On-Demand Oral						
07:00 - 08:30	ON-DEMAND SYMPOSIA (VIRTUAL GALLERY)					
	Auditorium VII	Auditorium VI	Auditorium V	Auditorium VIII	Auditorium II	Auditorium III + IV
08:00 - 08:30	PLENARY LECTURE 7: FROM LAB TO CLINIC: PROGRESS AND CHALLENGES IN ALPHA-SYNUCLEIN BASED THERAPIES FOR PARKINSON'S DISEASE					
08:30 - 08:40	BREAK					
08:40 - 10:40	ABETA TARGETING THERAPIES IN AD 2	BIOMARKERS IN CLINICAL USE ACROSS DEMENTIAS	TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS	FLUID, IMAGING AND DIGITAL MARKERS	TAU MECHANISMS 3	UBIQUITIN, AUTOPHAGY-LYSOSOMAL PATHWAYS
10:40 - 11:10	EXHIBITION, POSTERS AND COFFEE BREAK					
11:10 - 13:10	AD THERAPY: TARGETING TAU	BIOMARKERS AND MULTIMODAL IMAGING IN AD, PD, STROKE AND CREUTZFELDT-JAKOB DISEASE	CHOLINERGIC MECHANISMS IN AD AND PD (2)	PD, LBD: MECHANISMS, PATHOPHYSIOLOGY	VASCULAR DISEASES: MECHANISMS, PATHOPHYSIOLOGY	SORL1
13:10 - 14:10	EXHIBITION, POSTERS, LUNCH & INFORMAL NETWORKING WITH PROFESSORS					
14:10 - 16:10	FORUM 6: THERAPY FOR AD, PD & LBD: MAJOR ETIOLOGICAL UNANSWERED QUESTIONS, MISSING TARGETS, AND FUNCTIONAL MARKERS (14:10 - 15:10)	PD AND LBD: ADVANCES IN DIAGNOSIS AND DRUG DEVELOPMENT (14:10 - 16:10)	SECRETASES AND APP PROCESSING (14:10 - 16:10)	α -SYNUCLEINOPATHIES: MECHANISMS, PATHOPHYSIOLOGY AND MODELLING OF PROGRESSION (14:10 - 16:10)	COMORBIDITIES AND NEUROPSYCHIATRIC CONSEQUENCES OF AD, PD, LBD AND COVID-19 (14:10 - 16:10)	FLUID BIOMARKERS AND IMAGING 4 (14:10 - 16:10)
	FORUM 7: DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARD APPROVAL - WHAT COULD BE PROMISING STRATEGIES? (15:20 - 16:20)					
16:10 - 16:40	EXHIBITION, POSTERS AND COFFEE BREAK					
16:40 - 18:55	TRANSLATIONAL DRUG DISCOVERY AND EXPERIMENTAL MODELS 5	ADVANCES IN AD DRUG DEVELOPMENT 2	EEG, SLEEP, AND VIRTUAL ASSESSMENT TOOLS	ADVANCES IN PD AND LBD DRUG DEVELOPMENT	NEURODEGENERATION: DIVERSE MECHANISMS	NEURODEGENERATION: DIVERSE MECHANISMS FLUID BIOMARKERS AND IMAGING
19:00	CLOSING CEREMONY					

